SarajevoD, I would lean more towards delisting as well. NASDAQ given 2 extensions and Cytrx have at least couple areas of deficiencies. But, the company can still ask for more time and ultimately it's up to NASDAQ.
Their reasoning is on the recent deal with NantCell and potential milestone payment upon conditions with the Aldox deal. NASDAQ may see that the company have hope and not a shell with no real product.
So what we going to see is people bailing out as we get closer to the final date. But, Cytrx won't get a letter until 8/21 when their time is up. So, it's not immediate doom just yet.
Those like myself have already sold a good portion to limit our risk. Rest will hold no matter what. Shorts are betting on delisting as well. So this seems to suggest we go a bit lower in the coming weeks without any new development from the company.
Either way, after the delisting problem passes, longs should return because ultimately long term value is still there with this deal however bad it might be for original investors. But, to us new guys buying at 0.6 is too good to pass up.
A lot of us want to buy into the stock but this might not be the best time due to the delisting threat. If it does end up OTC, I'm sure we pickup a lot cheaper shares, but if it gets another extension, we still buy in for the long haul.
News 
Market Data 
Discover 
